Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis
JACC · 2025-11 · 86 (21) · 1983-1996
DOI: 10.1016/j.jacc.2025.08.025 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2025-11. Verfasst von Niekbachsh Mohammadnia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Colchicine, Clonal Hematopoiesis, Coronary Artery Disease. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: American Heart Association-American Stroke Association, NHLBI NIH HHS, NHLBI.
Abstract (Originalsprache)
BACKGROUND: Clonal hematopoiesis (CH) is an aging-related hematologic condition associated with increased risk for cardiovascular events. Larger CH clones associate more strongly with cardiovascular risk. Preclinical data indicate that inflammatory signaling drives expansion of CH clones and CH-associated cardiovascular disease. However, the effect of anti-inflammatory therapies on CH clonal dynamics in humans is unclear. OBJECTIVES: The goal of this study was to test the association of randomization to colchicine vs placebo with CH growth in participants with chronic coronary artery disease. It also assessed the association of colchicine use with change in inflammatory biomarkers over time according to CH status. METHODS: In this exploratory substudy of the LoDoCo2 (Low-Dose Colchicine 2) trial, high-coverage targeted sequencing was used to detect CH driver mutations and to quantify variant allele frequency at 4 timepoints: baseline, after a 30-day open-label colchicine run-in phase (0.5 mg daily), 1 year postrandomization to colchicine or placebo, and at end of study (median follow-up of 25.0 months). Clonal dynamics were assessed by using a generalized linear mixed model. High-sensitivity C-reactive protein and interleukin-6 were additionally measured at baseline, randomization, and 1 year postrandomization. RESULTS: In total, 854 participants contributed 2,047 observations across 4 timepoints, including before and after the prerandomization colchicine run-in period. Randomization to placebo was associated with a 14.9% annual increase in CH clone size (βtime = 0.14; 95% CI: 0.08 to 0.21) vs a nonsignificant 6.3% increase with colchicine (βtime on colchicine: 0.06; 95% CI: -0.01 to 0.14), although this difference between treatment arms was not statistically significant (Pinteraction = 0.13). Compared with placebo, colchicine was associated with attenuated clonal growth in TET2 CH (βtime on colchicine: 0.09 [95% CI: -0.04 to 0.22]; βtime placebo: 0.27 [95% CI: 0.16 to 0.37]; Pinteraction= 0.04). Among individuals with non-DNMT3A CH, interleukin-6 levels increased to a lesser extent in those receiving colchicine vs placebo over 1 year (30.0% vs 98.1% increase, respectively; Pinteraction = 0.01). CONCLUSIONS: In this exploratory analysis, treatment with low-dose colchicine was associated with attenuated clonal expansion in TET2 CH. These findings suggest the potential for colchicine to curb the proliferative advantage of key CH driver mutations and to mitigate their associated risk of cardiovascular disease. Further validation in prospective studies is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Science for Life Laboratory, University of Gothenburg, Gothenburg, Sweden.
- Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the Netherlands.
- Dutch Network for Cardiovascular Research (WCN), Utrecht, the Netherlands; Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands.
Förderung
- American Heart Association-American Stroke Association
- NHLBI NIH HHS
- NHLBI
- American Heart Association Inc
Zitieren
APA
Mohammadnia, N., Xue, L., Vestjens, L. T. W., Uddin, M. M., Niroula, A., de Kleijn, D. P. V., Mosterd, A., Fiolet, A. T. L., Nakao, T., Eikelboom, J. W., Cetinyurek-Yavuz, A., Peloso, G. M., Bax, W. A., Riksen, N. P., Natarajan, P., Cornel, J. H., El Messaoudi, S., & Honigberg, M. C. (2025). Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis. JACC, 86(21), 1983-1996. https://doi.org/10.1016/j.jacc.2025.08.025
Vancouver
Mohammadnia N, Xue L, Vestjens LTW, Uddin MM, Niroula A, de Kleijn DPV, et al. Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis. JACC. 2025;86(21):1983-1996. doi:10.1016/j.jacc.2025.08.025
BibTeX
@article{Mohammadnia2025,
author = {Mohammadnia, Niekbachsh and Xue, Liying and Vestjens, Lucas T W and Uddin, Md Mesbah and Niroula, Abhishek and de Kleijn, Dominique P V and Mosterd, Arend and Fiolet, Aernoud T L and Nakao, Tetsushi and Eikelboom, John W and Cetinyurek-Yavuz, Aysun and Peloso, Gina M and Bax, Willem A and Riksen, Niels P and Natarajan, Pradeep and Cornel, Jan H and El Messaoudi, Saloua and Honigberg, Michael C},
title = {Colchicine and Longitudinal Dynamics of Clonal Hematopoiesis},
journal = {JACC},
year = {2025},
volume = {86},
number = {21},
pages = {1983--1996},
doi = {10.1016/j.jacc.2025.08.025}
}
EUVIMED